IGI reports 75% response rate in multiple myeloma drug trial
Ichnos Glenmark Innovation (IGI) announced today that its experimental cancer drug ISB 2001 showed a 75 per cent overall response rate in patients with relapsed/refractory multiple myeloma during its Phase 1 clinical trial. The company will present these first-time results at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego. The shares…